文献速递生殖医学

供卵者卵巢刺激的系统综述与荟萃分析

Ovarian stimulation for oocyte donation: a systematic review and meta-analysis.
PubMed 文献 · Hum Reprod Update · 2021-01-01

该研究为首个系统综述,旨在总结供卵者卵巢刺激的现有证据,检索PubMed和Embase至2020年5月,纳入57篇文献。主要结论:GnRH激动剂扳机是金标准,可消除OHSS且不影响妊娠率;拮抗剂与激动剂在卵巢反应上无差异;孕激素方案与拮抗剂方案获卵数和妊娠率无显著差异;鲜卵与玻璃化卵妊娠结局相似。

要点

  • GnRH激动剂扳机应作为所有供卵者的金标准,以消除OHSS风险。
  • 孕激素方案与拮抗剂方案获卵数(MD 0.23)和妊娠率(OR 0.87)无显著差异。
  • 鲜卵与玻璃化供卵的妊娠结局相似,但新生儿长期安全性证据不足。

核心结论

  • GnRH激动剂扳机是供卵者卵巢刺激的金标准,可实际消除OHSS且不降低妊娠率。
  • 孕激素方案与拮抗剂方案在获卵数和妊娠率上无显著差异。
  • 鲜卵与玻璃化供卵的妊娠结局相似。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed和Embase至2020年5月,遵循PRISMA指南。
  • 共纳入57篇文献,使用ROBINS-I和ROB2评估质量,必要时行荟萃分析。

主要发现

  • 窦卵泡计数和抗苗勒管激素与卵巢反应相关,但区分不良或过度反应的价值有限。
  • 五项RCT比较不同促性腺激素,因高异质性未行荟萃分析。
  • GnRH拮抗剂与激动剂在卵巢反应上无差异。
  • 孕激素方案与拮抗剂方案获卵数MD 0.23(95%CI 0.58-1.05,n=2147,6项研究,I2=13%,P=0.33)。
  • 孕激素方案与拮抗剂方案临床妊娠率OR 0.87(95%CI 0.60-1.26,n=2260,I2=72%,P<0.01)。

关键数值与推荐

  • GnRH激动剂扳机获卵率极佳,OHSS实际消除,受体妊娠率无差异(4项研究,OR 0.86,95%CI 0.58-1.26,I2=0%)。
  • 卵巢刺激期间使用左炔诺孕酮宫内节育器或孕激素避孕药不影响获卵数和临床妊娠率。
  • 超声监测足以满足供卵者刺激周期的随访。

临床怎么用

  • 供卵者卵巢刺激应优先使用GnRH激动剂扳机以预防OHSS。
  • 孕激素方案可作为拮抗剂方案的替代选择。
  • 鲜卵与玻璃化卵均可用于供卵,妊娠结局相似。

局限性

  • 新生儿长期安全性证据不足。
  • 促性腺激素比较因高异质性无法荟萃分析。
  • 需更多针对供卵者的卵巢刺激方案临床研究,尤其是新生儿长期安全性和避孕效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Since its introduction in the 1980s, oocyte donation (OD) has been largely integrated into ART. Lately, both demand and the indications for OD have increased greatly. Oocyte donors are healthy and potentially fertile women undergoing voluntarily ovarian stimulation (OS). Selection of the optimal type of stimulation is of paramount importance in order to achieve the most favourable outcomes for the oocyte recipients, but most importantly for the safety of the oocyte donors. OBJECTIVE AND RATIONALE: This is the first systematic review (SR) with the objective to summarize the current evidence on OS in oocyte donors. The scope of this SR was to evaluate the OD programme by assessing four different aspects: how to assess the ovarian response prior to stimulation; how to plan the OS (gonadotrophins; LH suppression; ovulation trigger; when to start OS); how to control for the risk of ovarian hyperstimulation syndrome (OHSS) and other complications; and the differences between the use of fresh versus vitrified donated oocytes. SEARCH METHODS: A systematic literature search was conducted in May 2020, according to PRISMA guidelines in the databases PubMed and Embase, using a string that combined synonyms for oocytes, donation, banking, freezing, complications and reproductive outcomes. Studies reporting on the safety and/or efficacy of OS in oocyte donors were identified. The quality of the included studies was assessed using ROBINS-I and ROB2. Meta-analysis was performed where appropriate. Data were combined to calculate mean differences (MD) for continuous variables and odd ratios (OR) for binary data with their corresponding 95% CIs. Heterogeneity between the included studies was assessed using I2 and tau statistics. OUTCOMES: In total, 57 manuscripts were selected for the review, out of 191 citations identified. Antral follicle count and anti-Müllerian hormone levels correlate with ovarian response to OS in OD but have limited value to discriminate donors who are likely to show either impaired or excessive response. Five randomized controlled trials compared different type of gonadotrophins as part of OS in oocyte donors; owing to high heterogeneity, meta-analysis was precluded. When comparing different types of LH control, namely GnRH antagonist versus agonist, the studies showed no differences in ovarian response. Use of progesterone primed ovarian stimulation protocols has been evaluated in seven studies: the evidence has shown little or no difference, compared to GnRH antagonist protocols, in mean number of retrieved oocytes (MD 0.23, [95% CI 0.58-1.05], n = 2147; 6 studies; I2 = 13%, P = 0.33) and in clinical pregnancy rates among recipients (OR 0.87 [95% CI 0.60-1.26], n = 2260, I2 = 72%, P < 0.01). There is insufficient evidence on long-term safety for babies born. GnRH agonist triggering is the gold standard and should be used in all oocyte donors, given the excellent oocyte retrieval rates, the practical elimination of OHSS and no differences in pregnancy rates in recipients (four studies, OR 0.86, 95%CI 0.58-1.26; I2 = 0%). OS in OD is a safe procedure with a low rate of hospitalization after oocyte retrieval. The use of a levonorgestrel intrauterine device or a progestin contraceptive pill during OS does not impact the number of oocytes retrieved or the clinical pregnancy rate in recipients. Ultrasound monitoring seems enough for an adequate follow up of the stimulation cycle in OD. Use of fresh versus vitrified donated oocytes yielded similar pregnancy outcomes. WIDER IMPLICATIONS: This update will be helpful in the clinical management of OS in OD based on the most recent knowledge and recommendations, and possibly in the management of women under 35 years undergoing oocyte vitrification for social freezing, owing to the population similarities. More clinical research is needed on OS protocols that are specifically designed for OD, especially in term of the long-term safety for newborns, effective contraception during OS, and treatment satisfaction.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Martinez F, Racca A, Rodríguez I, et al. Ovarian stimulation for oocyte donation: a systematic review and meta-analysis. Hum Reprod Update. 2021. PMID: 33742206. doi:10.1093/humupd/dmab008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。